Actualités Ocean Biomedical Inc - OCEA | Actions NASDAQ

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Premium

Securities Registration Statement (s-1/a)

0001869974 true S-1/A

Ocean Biomedical (NASDAQ: OCEA) Announces Initiation of Coverage by Taglich Brothers with a Share Price Target of $20.

Providence, RI, June 01, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a new-era biopharma...

Current Report Filing (8-k)

0001869974 false 0001869974 2023-05-25 2023-05-25 0001869974...

Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Addition to the Russell 2000® Index

Providence, RI, May 25, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical (NASDAQ: OCEA) announced today that it is...

Quarterly Report (10-q)

0001869974 false Q1 --12-31...

Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Award for Novel Cancer Immunotherapy Treatment, Granted for Prostate Cancer, Colon Cancer, Ovarian Cancer, Kidney Cancer, Breast Cancer, Glioblastoma, Melanoma, and Lung Cancer.

Latest patent broadens protection around OCEA’s platform of first-in-class anti-CHi3L1 therapeutic...

Current Report Filing (8-k)

0001869974 false 0001869974 2023-05-15 2023-05-15 0001869974...

Ocean Biomedical, Inc. Enters into a $25 Million Convertible Note Facility

Providence, RI, May 16, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company...

Notification That Quarterly Report Will Be Submitted Late (nt 10-q)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ...

Ocean Biomedical (NASDAQ: OCEA) Announces 70% Increase in Price Target by EF Hutton from $10 to $17 on New Glioblastoma Results Validating Profound Tumor Suppression with Anti-Chi3L1 Antibody

Providence, RI, May 01, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company...

Ocean Biomedical (NASDAQ: OCEA) Announces New Glioblastoma Results Validating Profound Tumor Suppression with Anti-Chi3L1 Antibody

Results published in peer-reviewed Cancer Research share novel insights into Chi3L1’s role in modulating Glioma...

Ocean Biomedical (NASDAQ: OCEA) on World Malaria Day Announces Sharing of New Malaria Vaccine Paradigm at PATH Malaria Research Retreat in Washington, DC, by Scientific Co-founder Dr. Jonathan Kurtis

Providence, RI, April 25, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company...

Securities Registration Statement (s-1)

0001869974 false

Ocean Biomedical (NASDAQ: OCEA) Announces Notice of Allowance for U.S. Patent Application for Breakthrough Pulmonary Fibrosis Treatments Issued to Scientific Co-founder Dr. Jack A. Elias.

Providence, RI, April 20, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company...

$134 Million in Financial Backing for Innovative Research and IND Fillings Announced by Ocean Biomedical (NASDAQ: OCEA); Provides Latest Updates on Advancement of Platform, Novel Discoveries in Malaria, Pulmonary Fibrosis and Oncology

Providence, RI, April 17, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (“Ocean”), a biopharma company...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Ocean Biomedical Inc (OCEA)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

OCEA Actualités

Securities Registration Statement (s-1/a)

Ocean Biomedical (NASDAQ: OCEA) Announces Initiation of Coverage by Taglich Brothers with a Share Price Target of $20.

Current Report Filing (8-k)

Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Addition to the Russell 2000® Index

Quarterly Report (10-q)

Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Award for Novel Cancer Immunotherapy Treatment, Granted for Prostate Cancer, Colon Cancer, Ovarian Cancer, Kidney Cancer, Breast Cancer, Glioblastoma, Melanoma, and Lung Cancer.

Current Report Filing (8-k)

Ocean Biomedical, Inc. Enters into a $25 Million Convertible Note Facility

Notification That Quarterly Report Will Be Submitted Late (nt 10-q)

Ocean Biomedical (NASDAQ: OCEA) Announces 70% Increase in Price Target by EF Hutton from $10 to $17 on New Glioblastoma Results Validating Profound Tumor Suppression with Anti-Chi3L1 Antibody

Ocean Biomedical (NASDAQ: OCEA) Announces New Glioblastoma Results Validating Profound Tumor Suppression with Anti-Chi3L1 Antibody

Ocean Biomedical (NASDAQ: OCEA) on World Malaria Day Announces Sharing of New Malaria Vaccine Paradigm at PATH Malaria Research Retreat in Washington, DC, by Scientific Co-founder Dr. Jonathan Kurtis

Securities Registration Statement (s-1)

Ocean Biomedical (NASDAQ: OCEA) Announces Notice of Allowance for U.S. Patent Application for Breakthrough Pulmonary Fibrosis Treatments Issued to Scientific Co-founder Dr. Jack A. Elias.

$134 Million in Financial Backing for Innovative Research and IND Fillings Announced by Ocean Biomedical (NASDAQ: OCEA); Provides Latest Updates on Advancement of Platform, Novel Discoveries in Malaria, Pulmonary Fibrosis and Oncology

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Ocean Biomedical Inc (OCEA) Actualités

Ocean Biomedical Inc (OCEA)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

OCEA Actualités

Securities Registration Statement (s-1/a)

Ocean Biomedical (NASDAQ: OCEA) Announces Initiation of Coverage by Taglich Brothers with a Share Price Target of $20.

Current Report Filing (8-k)

Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Addition to the Russell 2000® Index

Quarterly Report (10-q)

Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Award for Novel Cancer Immunotherapy Treatment, Granted for Prostate Cancer, Colon Cancer, Ovarian Cancer, Kidney Cancer, Breast Cancer, Glioblastoma, Melanoma, and Lung Cancer.

Current Report Filing (8-k)

Ocean Biomedical, Inc. Enters into a $25 Million Convertible Note Facility

Notification That Quarterly Report Will Be Submitted Late (nt 10-q)

Ocean Biomedical (NASDAQ: OCEA) Announces 70% Increase in Price Target by EF Hutton from $10 to $17 on New Glioblastoma Results Validating Profound Tumor Suppression with Anti-Chi3L1 Antibody

Ocean Biomedical (NASDAQ: OCEA) Announces New Glioblastoma Results Validating Profound Tumor Suppression with Anti-Chi3L1 Antibody

Ocean Biomedical (NASDAQ: OCEA) on World Malaria Day Announces Sharing of New Malaria Vaccine Paradigm at PATH Malaria Research Retreat in Washington, DC, by Scientific Co-founder Dr. Jonathan Kurtis

Securities Registration Statement (s-1)

Ocean Biomedical (NASDAQ: OCEA) Announces Notice of Allowance for U.S. Patent Application for Breakthrough Pulmonary Fibrosis Treatments Issued to Scientific Co-founder Dr. Jack A. Elias.

$134 Million in Financial Backing for Innovative Research and IND Fillings Announced by Ocean Biomedical (NASDAQ: OCEA); Provides Latest Updates on Advancement of Platform, Novel Discoveries in Malaria, Pulmonary Fibrosis and Oncology

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application